Publication at Faculty of Mathematics and Physics, Faculty of Law |
2014
Abstract
The article responds to three major decisions in the EU Court of Justice preliminary rulings from the end of 2013, regarding the interpretation of Art. 3 point. a) c) of Regulation no. 469/2009 concerning the supplementary protection certificate for medicinal products, thus the conditions under which they can obtain supplementary protection certificate. This is a decision in the case of Eli Lilly in Human Genome Sciences (C-493/12), Actavis Group at Sanofi (C-443/12) and Georgetown University (C-484/12).